Systems and methods for classifying tumors
AssigneePresident and Fellows of Harvard College
InventorsDoga C. GULHAN, Peter J. PARK
Life of this patent
Estimating the term…
Abstract
Disclosed are systems and methods that can identify mutational signatures relevant to various cancers and/or treatments using genetic data from the tumors. This includes using a likelihood based measure, to compare clusters of tumor spectrums when the sample has sequenced only a sub-set of the genes with a targeted panel. In one example, by enabling panel-based identification of mutational signatures, our method substantially increases the number of patients that may be considered for treatments targeting HR deficiency.
Claims20
A method of classifying a tumor of a patient, the method comprising:
- obtaining a sample of a patient's tumor tissue;
- performing DNA sequencing on the sample to output a set of genetic data;
- performing a mutation analysis on the set of genetic data to output a set of mutations;
- determining a sample mutational spectrum based on the set of mutations;
- comparing the mutational spectrum to a set of clusters comprising different mutational spectrums to determine a matching cluster;
- and
- outputting an indication of a mutational signature of the sample based on the matching cluster.
A method of classifying a tumor of a patient, the method comprising:
- receiving a mutation analysis on a subset of genes on a sample of a patient's tumor tissue to output a set of mutations;
- determining a sample mutational spectrum based on the set of mutations;
- comparing the mutational spectrum to a set of clusters comprising different mutational spectrums to determine a matching cluster;
- and
- determining a mutational signature of the sample based on the matching cluster;
- and
- treating the patient based on the determined mutational signature.
A method of classifying a tumor of a patient, the method comprising:
- receiving a gene analysis on a subset of genes on a sample of a patient's tumor tissue from to output a set of mutations;
- determining a signature three mutation profile status based on the set of mutations;
- and
- treating the patient with a PARP inhibitor based on the signature three mutation profile status.
Dependencies are inferred from the claim text.